6605 Merrill Creek Parkway
79 articles with Altasciences
Altasciences Expands Strategic Support for Early Drug Development in Europe and Adds Key Employees to Its Preclinical Team in North America
Altasciences hired two expert advisors to support its strategic growth in Europe, while its preclinical team continues to expand with the addition of two key employees.
Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s
Alzamend Neuro, Inc. today announced that it contracted with Altasciences Clinical Kansas (“ Altasciences ”) and iResearch Atlanta, LLC (“iResearch”) to manage and conduct, respectively, its Phase IIA multiple ascending dose (“MAD”) study in patients with mild to moderate Alzheimer’s Disease (“Alzheimer’s”).
Altasciences announced the appointment of Dr. Wendell P. Davis, D.V.M., Dipl. ACVP, as Vice President, Pathology, effective February 7, 2022.
Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the Knee
Altasciences is pleased to have been chosen by Virpax® Pharmaceuticals, Inc. (“Virpax”) (NASDAQ:VRPX) to conduct a first-in-human study of Epoladerm™ (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee.
Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof of concept, announced today the completed acquisition of Sinclair Research, a preclinical CRO located in the Midwest.
Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee
Virpax ® Pharmaceuticals, Inc. signed a clinical trial agreement with Altasciences Company, Inc. for a First in Human study investigating Epoladerm™ for pain associated with osteoarthritis of the knee.
Altasciences Chosen by Respira Technologies, Inc. as Drug Product Manufacturing Partner for the World’s First Inhaled Nicotine Replacement Therapy (NRT)
Altasciences’ pharmaceutical contract manufacturing site in Philadelphia, PA, has been chosen by Respira Technologies, Inc. to manufacture proprietary drug products for the world’s first inhaled smoking cessation therapy.
Altasciences, a leading drug development solution company, announced the completion of a second expansion of their ligand binding laboratory to meet the high demand for quality bioanalytical services.
Two new notable biotech/biopharma acquisitions were reported this week: Athenex has acquired Kuur Therapeutics, while Altasciences has acquired preclinical CRO Calvert Laboratories.
Audax Private Equity (“Audax”) today announced that it has successfully completed the previously announced sale of Altasciences to Novo Holdings. Altasciences is a leading, fully-integrated, early drug development services platform, providing the pharmaceutical and biotech industries with a trusted partner for drug development, from preclinical safety testing through clinical proof-of-concept studies.
Altasciences , working with the National Research Council of Canada (NRC), has qualified a quantitative serological assay for the detection of SARS-CoV-2 IgG antibodies, to support vaccine development in studies from discovery to Phase II.
Altasciences Conducts Preclinical Studies in Support of Verve Therapeutics’ Gene Editing Approach for Cardiovascular Disease
Altasciences is proud to have conducted preclinical studies for Verve Therapeutics that support the development and advancement of Verve’s gene editing approach to treating cardiovascular diseases. Altasciences’ Seattle team performed intravenous preclinical studies, including supporting analyses of pharmacodynamic markers and whole liver DNA editing
Altasciences, a fully integrated early phase CRO/CDMO has started the expansion of their CDMO facility in Philadelphia, PA. The additional 35,000-square-foot building directly adjoins the current location, and will be fully renovated to meet the growing business needs.
Altasciences announced today the appointment of Dr. Joseph A. Francisco as Chief Toxicologist, effective June 22, 2020.
Altasciences announced today the appointment of Dr. Gaetano Morelli as Chief Medical Officer, effective May 14, 2020. Dr. Morelli is a member of the College of Physicians of Québec, Canada, with over 30 years' medical experience and over 20 years' global clinical research background. He joined Altasciences in 2013 as a GI consultant and then signed on with Altasciences in 2017, first as Medical Advisor, then Clinical PI, and now Chief Medic
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS).
Altasciences , a CRO in the U.S. and Canada specializing in a flexible, innovative approach to comprehensive early stage drug development, announced today that they have entered into an agreement with Amador Bioscience , a translational and consulting clinical research organization located in China and the U.S. This partnership aims to expand world-class capabilities and resources to promote drug development in China and North America.
Altasciences announced the addition of Paul Sidney to their Compliance and Regulatory Affairs team as Senior Director
Martin will apply his extensive knowledge and experience to guide internal and external clients throughout their bioanalysis and immunomodulation analysis projects.
Dr. Gorman became a diplomate of the American College of Laboratory Animal Medicine in 2018.